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Introduction
Heart failure is broadly described as an inability of the heart to effectively pump and supply blood to the body. In response to insufficient blood flow, the sympathetic nervous system produces increased amounts of catecholamines to stimulate β-adrenergic receptors, which are part of the G protein-coupled receptor (GPCR) superfamily (Salazar et al., 2007; Belmonte and Blaxall, 2011) . However, the prolonged stimulation of GPCRs initiates the upregulation and phosphorylation by GPCR kinases (GRKs), which targets these receptors for arrestin binding and internalization (Ferguson et al., 1996; Ribas et al., 2007) . Receptor internalization reduces the number of receptors present on the cell surface, thus diminishing the responsiveness to agonists (Ferguson et al., 1996) .
There are seven different GRKs found in humans, which are divided into the GRK1 (GRK1 and 7), GRK2 (GRK2 and 3), and GRK4 (GRK4, 5, and 6) subfamilies, all of which belong of the protein kinase A, G, and C (AGC) family of Ser/Thr protein kinases. GRKs 2 and 5 are the dominant GRKs in the myocardium and are upregulated during heart failure (Dzimiri et al., 2004; Montó et al., 2012) . A series of studies have shown that selective inhibition of GRK2 activity is a promising approach to improve cardiac function during heart failure (Rockman et al., 1998; Raake et al., 2013; Schumacher et al., 2015) .
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subsite while the C ring occupies the polyphosphate subsite. However, neither occupy the hydrophobic pocket of the active site as was observed with the Takeda compound (Figure 2b) known as CMPD101 or compound 115h (Ikeda et al., 2007; Thal et al., 2011; Okawa et al., 2017) . We subsequently used a rational drug design approach to generate derivatives of both GSK180736A and paroxetine with substituents appended onto the C ring via an amide linker in order to occupy the hydrophobic pocket (Waldschmidt et al., 2016 (Waldschmidt et al., , 2017 .
We hypothesized that due to the similar binding modes of GSK180736A and paroxetine (Figure 2) , their structure-activity relationships would be translatable. Although this turned out generally not to be the case, overall the addition of amide-linked D-ring substituents to these scaffolds did lead to increases in potency in each class. In the case of GSK180736A, several substituents enabled us to build in selectivity for GRK2 over other kinases, especially Rhoassociated coiled-coil containing kinase 1 (ROCK1) for which this compound was originally designed to inhibit (Sehon et al., 2008) . We were also interested in understanding if the hingebinding moiety, an indazole in the case of GSK180736A and a benzodioxole in the case of paroxetine, was interchangeable. However, it was observed in the case of the GSK180736A scaffold that exchanging the indazole for a benzodioxole resulted in a severe loss of activity (Waldschmidt et al., 2016) .
We next hypothesized that by exchanging the benzodioxole moiety in the paroxetine scaffold with an indazole would instead result in increased potency due to its stronger interactions with the hinge (two hydrogen bonds for indazole versus a hydrogen bond and a carbon-oxygen hydrogen bond for benzodioxole). Thus, we synthesized a series of paroxetine hybrids in which the benzodioxole ring was exchanged for indazole. These indazole-paroxetine hybrids in general showed an increase in GRK2 potency relative to their benzodioxole
6 counterparts, however lost selectivity. To understand the molecular basis for enhanced potency and loss of selectivity, we crystallized several of these hybrid compounds in complex with GRK2-Gbg. These and prior crystallographic studies show that the indazole warhead locks the kinase domain into a specific conformation that leads to one particular crystal form, whereas the benzodioxole-based compounds lead to a variety of crystal forms with subtly different conformations of the kinase domain. Our results indicate that the identity and strength of the hinge-binding moiety is important for dictating the overall conformation of the GRK2 kinase domain, and that weaker hinge interactions allow access to a broader distribution of subtly different conformational states. The selectivity generally exhibited by benzodioxole-based compounds for GRK2 may therefore result from the ability of its kinase domain to access conformational states not readily available to closely related enzymes.
8 using ImageQuant, as previously described (Thal et al., 2012) . Data was fit to a three-parameter dose-inhibitor response curve with a fixed Hill slope of 1 and the bottom constrained to 0 using GraphPad Prism. A maximum of two outliers were removed per individual dataset and in some cases an entire dataset was excluded from the analysis.
Mouse Liver Microsome Assays. Metabolic stability was determined using CD-1 mouse liver microsomes. Reactions consisted of 1 µM compound, 0.5 mg/mL microsomes, 1.7 mM NADPH in 0.1 M phosphate buffer pH 7.4 supplemented with 3.3 mM MgCl 2 , incubated at 37 °C. Aliquots of 40 µL were taken at 0, 5, 10, 15, 30, 45, and 60 min and quenched in 3 volumes of cold acetonitrile containing 100 ng/mL internal standard. Samples were centrifuged at 15,000 rpm for 10 min and the supernatant was analyzed by LC-MS/MS. Protein Expression and Purification. Human GRK2 S670A with a C-terminal hexahistidine tag was expressed in High-Five cells using the Bac-to-Bac insect cell expression system (Life Technologies, Carlsbad, CA). Cells were harvested 48 h post infection and lysed.
GRK2 was purified from the clarified lysate as described previously for GRK1 using nickelnitrilotriacetic acid affinity and cation exchange chromatography (Singh et al., 2008) . Fractions containing GRK2 were pooled and further purified on a Sephadex 200 column into 20 mM HEPES pH 7.5, 100 mM NaCl, and 1 mM DTT. Soluble human Gb 1 g 2 (C68S mutant) containing an N-terminal (on the Gb 1 unit) hexahistidine tag was expressed using a dual-promoter insect cell expression vector in High-Five cells. The cells were harvested 48 h post infection and lysed.
Gb 1 g 2 was purified from the clarified lysate as described previously using nickel-nitrilotriacetic acid affinity and anion exchange chromatography (Kozasa, 2004) . Fractions containing Gb 1 g 2 were pooled and further purified on a Sephadex 200 column into 20 mM HEPES pH 8.0, 100 mM NaCl, and 1 mM DTT.
This article has not been copyedited and formatted. The final version may differ from this version. Crystal Structure Determination. Purified GRK2 (S670A) and soluble Gb 1 g 2 (C68S) were mixed in a 1.2:1 molar ratio with a final protein concentration of approximately 10 mg/mL. Inhibitor (500 µM) and MgCl 2 (2 mM) were added to the protein mixture and allowed to incubate on ice for 30 min prior to filtration through a 0.2 µm Nanosep centrifugal device (Pall Laboratory, Port Washington, NY). Inhibitor complexes were crystallized as previously described by hanging drop vapor diffusion at 4 °C with drops consisting of 0.8 µL protein and 0.8 µL reservoir solution, which consisted of 50 mM MES pH 6.0, 0.8-1.2 M NaCl, and 8-16% PEG3350 (Thal et al., 2011 (Thal et al., , 2012 . Crystals generally appeared after 2-3 days and grew for 1-2 weeks. Crystals were harvested in a cryoprotectant solution consisting of the reservoir solution supplemented with 25% ethylene glycol and 500 µM inhibitor before being flash frozen in liquid nitrogen. Diffraction data was collected on the LS-CAT beamlines 21-ID-G and 21-ID-D at wavelengths of 0.97857 and 1.0332 Å, respectively. Data integration and scaling was performed with XDS (Sauter et al., 2013) or DIALS (Gildea et al., 2014) . The structures were solved using Phaser (McCoy et al., 2007) with PDB ID 4PNK as the search model. Reciprocal-space refinement was performed with PHENIX (Afonine et al., 2012) and alternated with local realspace refinement and model building using Coot (Emsley and Cowtan, 2004 ). Crystal refinement statistics are listed in Supplementary Table 1 . The final models were validated using MolProbity (Chen et al., 2010) prior to deposition in the Protein Data Bank under accession codes: 5WG3, 5WG4, and 5WG5.
Principal Component Analysis. Principal component analysis was previously performed
for the kinase domains of PKA, GRK1, GRK4 family members, and GRK2 that were previously deposited on the Protein Data Bank (Yao et al., 2017) . The kinase domains were aligned using core residues which were identified to be structurally invariant. Previous structural analysis of 49
This article has not been copyedited and formatted. The final version may differ from this version. GRK and 201 PKA structures revealed two distinct structural motions which were grouped into PC1 (72% of the structural variance) and PC2 (approximately 10% of the structural variance).
These structural motions corresponded to an opening and closing of the kinase domain mediated by the hinge connecting the small and large lobes (PC1) and a twisting motion between these domains (PC2). The GRK2 structures from this study were incorporated into the same analysis to benchmark their conformational states with respect to these previously published structures.
Myocyte Shortening Assays. Mouse cardiomyocytes were isolated from left-ventricular free wall and septum of C57/Bl6 mice as previously described (Song et al., 2008) . Cells were used within 2-8 h of isolation and plated on laminin-coated coverslips and bathed in HEPESbuffered (20 mM, pH 7.4) medium 199 containing 1.8 mM extracellular Ca 2+ . Coverslips were then mounted in the Dvorak-Stotler chamber for recording and bathed in 0.7 mL of fresh medium. Imaging was performed with a variable field-rate camera (Zeiss IM35, Ionoptix) using edge detection and sarcomere length. Peak contraction was measured as the percentage of cell shortening. Cells were paced at 1 Hz and treated with isoproterenol (0.5 µM) for 2 min, with pretreatment of either PBS as vehicle or CCG224061 (0.5 and 1 µM) for 10 min, and the contractions recorded (Thal et al., 2012) . 
Mouse Pharmacokinetic
Results
Synthesis.
Paroxetine hybrid compounds in which there is an indazole in place of the benzodioxole were prepared by a convergent approach (Scheme 1). Intermediate 7b was synthesized from commercially available 2-fluoro-5-methylphenol 1. Nitration of compound 1 proceeded first through the nitroso via sulfuric acid and sodium nitrite then nitric acid was used to afford nitro 2 (Flaugh et al., 1979) . Amine 3 was readily accessed via palladium reduction of nitro 2.
Acetylation followed by cyclization of the amine with isoamyl nitrite and subsequent hydrolysis yields 6-fluoro-1H-indazol-5-ol 4b (Iwakubo et al., 2007) . Silyl protection of the alcohol gives 5b. In the presence of catalytic dimethylaminopyridine the indazole is then Boc-protected giving regioisomers of 6b. Final silyl deprotection gives the free alcohol 7b. Intermediate 7a was synthesized from the commercially available 1H-indazol-5-ol 4a as described for 7b.
Analogs 11a and 11b were synthesized from intermediate 8 which was obtained as previously described (Scheme 2) (Waldschmidt et al., 2017) . Mesylation of alcohol 8 followed Synthesis of the indazole substituted non-hybrid analogs are shown in Scheme 3. Alcohol 12, which has previously been reported (Waldschmidt et al., 2017) , was then N-alkylated via two different methods. The N-ethyl 13a was achieved through substitution using ethyl iodide under basic conditions. The N-isopropyl 13b was prepared through reductive amination with acetone.
Respective N-substituted analogues (compound 14 is commercially available and 15 has been previously reported) were then mesylated at the benzylic alcohol which was subsequently displaced with alcohols 7a or 7b to give intermediates 16a-e. Final Boc deprotection yielded analogs 17a-e.
Structure-Activity Relationships
To investigate whether binding of paroxetine hybrids could be improved, we exchanged the benzodioxole moiety for an indazole, analogous to what is present in GSK180736A ( Table   1) . CCG224061 showed a 20-fold increase in potency for GRK2 (IC 50 = 66 nM) over paroxetine (IC 50 = 1.38 µM) (Thal et al., 2012) . However, this change also resulted in increased activity against GRK1 and 5, PKA, and ROCK1. Although CCG224061 was still selective for GRK2, the selectivity factor over ROCK1 was only 5-fold, versus more than 50-fold selectivity observed with paroxetine (Waldschmidt et al., 2017) . In an effort to improve selectivity, 2,6-dimethoxybenzylamide was appended to the fluorophenyl C-ring (CCG232406). Previously, this adduct gave the largest improvement in the GSK180736A scaffold (Waldschmidt et al., 2016) .
Compound CCG232406 indeed showed improvement in GRK2 selectivity over the other GRKs and PKA, and approximately 20-fold selectivity over ROCK1.
This article has not been copyedited and formatted. The final version may differ from this version. In a parallel attempt to improve selectivity, we appended two favorable adducts, 2-pyridylmethylamide and 3-pyrazolylmethylamide, discovered from our previous efforts using the paroxetine scaffold (Waldschmidt et al., 2017) to generate CCG257284 and CCG258748, respectively. CCG257284 showed no improvement in GRK2 potency relative to CCG224061 but resulted in pan-GRK inhibition with potencies similar to the analogous GSK180736A-based analog (CCG215022) (Waldschmidt et al., 2016) . CCG258748 exhibited our most potent GRK2 inhibition to date with an IC 50 of 8 nM. Although this compound displayed greater than 30-fold selectivity over the other GRKs and PKA, the IC 50 for GRK5 was still quite potent at 240 nM.
Lastly, we investigated alkylating the piperidine nitrogen of CCG224061 to improve selectivity ( Table 2) . N-methylation (CCG258001) resulted in a 4-fold decrease in GRK2 potency but much more dramatic decreases in potency for GRK1, GRK5, and PKA, resulting in >100 fold-selectivity for GRK2 over all three kinases. Increasing the size of the methyl to ethyl and isopropyl (CCG258211 and CCG258746, respectively) was not as well tolerated, in that the GRK2 potency dropped with increasing substituent size. Therefore, larger alkyl groups were not explored.
Metabolic Stability
In addition to improving the in vitro potency and selectivity for GRK2 we also aimed to generate analogs with more favorable pharmacokinetic (PK) properties and thus hopefully efficacy in vivo because the paroxetine scaffold is much better tolerated than GSK180736A (Waldschmidt et al., 2017) . The compounds were incubated with mouse liver microsomes (MLM) in order to test for metabolic stability ( Table 1) . The initial hit compound, paroxetine, had a half-life of 24.1 min in this MLM assay (Waldschmidt et al., 2017) . Replacing the benzodioxole ring with an indazole (CCG224061) resulted in a longer half-life of 30.3 min.
This article has not been copyedited and formatted. The final version may differ from this version. However, CCG257584 and CCG258748 did not show any improvement in metabolic stability compared to their respective benzodioxole analogs (CCG211998 and CCG258208). We also explored fluorination of the C6 position of the indazole ring to improve potency and improve metabolic stability as this was previously shown to be successful with similar compounds (Goodman et al., 2007; Sehon et al., 2008) . However, addition of a fluoro substituent to the A ring (CCG258002 and CCG258003) did not improve GRK2 potency and did not have a significant effect on the metabolic stability ( Table 1) .
Crystallography
Previously we were successful in obtaining crystals of GRK2-Gbg complexes bound to three paroxetine analogs containing a benzodioxole warhead and paroxetine (Thal et al., 2012; Waldschmidt et al., 2017) . These complexes crystallized in two different crystal forms (two C2 and one P2), whereas inhibitors based off the GSK180736A scaffold (which contain an indazole warhead) all crystallized in a C222 1 crystal form (Waldschmidt et al., 2016) (Table S1) . A previously reported benzolactam derivative of paroxetine (PDB ID: 4MK0), also crystallized with the same packing as the GSK180736A-based compounds (Homan et al., 2013) . Therefore, we hypothesized that the identity of the hinge-binding moiety is critical for not only determining potency towards GRK2 in these compounds but also dictating the conformation of the kinase domain and consequently the crystal form. The indazole and benzolactam moieties seem to be able to form stronger hinge interactions via multiple conventional hydrogen bonds, thereby stabilizing a consistent kinase conformation that allows GRK2 to crystallize in a reproducible way (Thal et al., 2012; Homan et al., 2013 Homan et al., , 2015 .
Consistent with this reasoning, the three indazole-paroxetine hybrids (CCG224061, CCG258284, and CCG258748) co-crystallized with GRK2-Gbg in this study also crystallized in This article has not been copyedited and formatted. The final version may differ from this version. the C222 1 space group. In all three complexes, the indazole forms two hydrogen bonds to the carbonyl oxygen of Asp272 and the backbone nitrogen of Met274 in the hinge (Figure 3) . As previously observed in other paroxetine complexes, there is an additional highly conserved hydrogen bond between the piperidine nitrogen of the paroxetine scaffold and the backbone carbonyl of Ala321. As expected, the D-ring amide linker of CCG258748 and CCG257284 made additional interactions. In the case of CCG258748, the carbonyl oxygen and amide nitrogen formed hydrogen bonds with the backbone nitrogen of Gly201 and the sidechain of Asp335, respectively (Figure 3c ). In the case of CCG257284 a hydrogen bond with the sidechain of Asp335 was not observed due to this residue being shifted slightly away from the ligand. Finally, in the case of CCG258748 the pyrazole is able to make additional hydrogen bonds with the sidechains of Glu239 and Lys220 that could explain its high potency (Figure 3c) . The pyridine nitrogen of CCG257284 does not appear to be able to make any interactions with the protein and is modeled with the nitrogen pointing out of the active site so that it can favorably interact with solvent ( Figure 3b ).
Structural Comparisons with Analogous GRK2-Inhibitor Complexes
We have previously published complexes with paroxetine, CCG211998, and CCG258208
(PDB IDs: 3V5W, 5UKK, and 5UKM, respectively), which are the benzodioxole analogs of the complexes of CCG224061, CCG257284, and CCG258784, respectively, that we report here (Thal et al., 2012; Waldschmidt et al., 2017) . Comparison of these structures thus give insights into how substituting indazole for benzodioxole in the paroxetine scaffold influences the overall conformation of the small and large lobes of the kinase domain, and therefore clues into the molecular basis for the remarkable selectivity underlying the benzodioxole-based compounds.
This article has not been copyedited and formatted. The final version may differ from this version. (Figure 4a) . However, in the case of paroxetine the interaction with Asp272 is weaker because it is a CH-O hydrogen bond. In the CCG224061 complex, the backbone of the hinge is pushed out a maximum of 0.6 Å at Asn275 compared to the paroxetine complex, and the P-loop (b1-b2 turn) exhibits a more closed conformation, exhibiting a 2.1 Å difference at the Ca of Gly201.
Differences were also observed in the b2-b3 and b4-b5 loops of up to 0.6 Å and 0.8 Å,
respectively. Additionally, a large portion of the active-site tether (AST, residues 493-500) is ordered in the CCG257284 complex relative to the CCG211998 complex.
This article has not been copyedited and formatted. The final version may differ from this version. (Figure 4c) , although the hydrogen bonds with the hinge are again stronger (shorter) in the case of CCG258748 (distances of 3.7 and 2.9 Å versus 3.8 and 3.1 Å, respectively). The hinge is displaced a maximum of 0.5 Å away from the active site in CCG258748 compared to the CCG2528208 complex. Additionally, the 3-pyrazolylmethylamide shows slightly different conformation and interactions in the hydrophobic subsite. Although in both CCG258748 and CCG258208 the two pyrazole nitrogens form hydrogen bonds with Lys220 and Glu239, CCG258208 forms an additional contact with Asp335 via its amide linker. The P-loop is shifted up to 0.6 Å at Gly201 away from the active site in the CCG258748 complex. Hinge interactions formed by CCG258748 also induce up to a 0.8 Å change of the b4-b5 loop, and a large shift in the b2-b3 loop (1.2 Å for the Ca of Asp212). There is a smaller change in the aB-aC loop compared to other analogous complexes, with a 0.7 Å shift for the Ca of Glu233. Additionally, the highly mobile AST is more ordered in the CCG258748 complex, allowing for an additional 5 residues (491-496) to be modelled.
The buried surface area (BSA) of each of these six ligands and their hinge-binding moieties was then compared ( Table 5 ). In general, the BSA of the indazole warhead was greater than that of benzodioxole. However, the entire BSA of CCG258748 and CCG257284 was less than observed with their respective benzodioxole analogs (CCG258208 and CCG211998, respectively), due to the differences in packing of the D rings and outward movements of the aB-aC loop.
Principal component analysis (PCA) was then performed to plot the conformation of the new ligand complexes in the 2D space spanned by PC1 and PC2, in which PC1 represents a This article has not been copyedited and formatted. The final version may differ from this version. concerted opening/closing of the kinase domain describing the largest variance across published GRK structures and PC2 is a twisting motion representing smaller structural variance (Yao et al., 2017) . This approach allows us to analyze in an unbiased way the global conformational changes of the kinase domain in response to binding different classes of inhibitors (in this case indazole vs. benzodioxole warheads). As expected, this analysis showed that the GRK2 complexes with the indazole-paroxetine hybrids (CCG224061, CCG257284, and CCG258748) all cluster closely together with several previously determined indazole-containing complexes (Figure 5 ). More specifically, all GRK2 complexes with indazole-containing compounds display similar PC1
compositions but exhibit greater variance along the PC2 coordinate (especially for entries 5HE0
and 5HE3). The GRK2 complexes with CCG224061 and CCG257284 showed almost identical PC1/PC2 compositions and ended up very close to the CCG224406 (a GSK analog, entry 5HE2) and GSK180736A (entry 4PNK) complexes. The GRK2 complex with CCG258748 was closest to 4MK0 (complex with a benzolactam-paroxetine analog) in PC space. On the other hand, the various benzodioxole complexes inhabit a much broader spectrum of conformational space. The CCG211998 (5UKK) complex showed the smallest displacement from the mean along PC1, perhaps consistent with the fact that this was the only complex thus far to crystallize in the space group P2.
Myocyte Shortening Assays
To investigate how indazole-paroxetine hybrids perform in a more in vivo environment, we tested CCG224061 with mouse cardiomyocytes and measured their ability to produce a contraction. The cardiomyocytes were harvested from adult mice and incubated with varying does of the inhibitors followed by a dose of the b-AR agonist isoproterenol. Paroxetine needed to be given at a dose of 10 µM in order to produce a significant response, whereas GSK180736A
This article has not been copyedited and formatted. The final version may differ from this version. showed a similar response at 1 µM (Thal et al., 2012; Waldschmidt et al., 2016) consistent with its 10-fold improvement in potency over paroxetine measured in vitro. Similarly, CCG224061
produced a significant increase in the maximum contraction response when dosed at 1 µM, consistent with its 20-fold higher potency for GRK2 compared to paroxetine (Table 3) .
Mouse Pharmacokinetic Studies
CCG224061 was then evaluated in a rapid mouse pharmacokinetics study ( Table 4) . In this study, the compound was injected intraperitoneally at 10 mg/kg and plasma samples collected after 30 min, 2, 4, and 7 h. The plasma levels of compound were quantified using MS/MS and a calibration curve. At 7 h the levels of CCG224061 were still quantifiable at 13 ng/mL (0.04 µM), however this is below the IC 50 of 0.066 µM. This compound showed a much lower area under the curve (AUC) than CCG258208, which was previously evaluated (Waldschmidt et al., 2017) . However, in the mouse liver microsome assays CCG224061 showed a 3-fold longer half-life than CCG258208. This suggests that CCG224061 may be cleared renally in addition to undergoing CYP-mediated metabolism.
Discussion
Understanding the molecular bases for potency and selectivity among closely related protein kinases is key to the rational design of improved GRK chemical probes. In this study, we hypothesized that substituting the benzodioxole moiety of paroxetine or its derivatives for an indazole would result in higher potency for GRK2. The hope was that they would retain the same or better selectivity as mediated by other substituents in each compound (namely the B, C and D rings). Indeed, these compounds showed corresponding increases in GRK2 potency.
Additionally, this class of indazole-paroxetine hybrids showed similar metabolic stability and This article has not been copyedited and formatted. The final version may differ from this version. efficacy in a mouse cardiomyocyte assay compared to previous paroxetine analogs. However, when CCG224061 was tested in mice it showed worse PK parameters than a previous benzodioxole analog (CCG258208) suggesting a renal clearance mechanism. The expected increase in potency was also met with corresponding increases in GRK5, PKA, and ROCK1
potency and the indazole series of compounds suffered from a 200-to 20-fold loss in selectivity compared to their benzodioxole-containing analogs.
To investigate the reasons for these changes in potency and selectivity, we determined crystal structures of GRK2-Gbg bound to three pairs of analogs in each series. The stronger hydrogen bond interactions and small increase in BSA for the indazole moiety likely leads to stronger interactions in the adenine binding pocket next to the hinge, leading to higher stability and a well-defined kinase domain conformation that consistently leads to the same crystal form (Table S2 ). The indazole-paroxetine analogs that contained amide-linked D rings also appeared to further stabilize the AST region, which passes over the active site. On the other hand, selectivity conferred by the benzodioxole hinge-binding moiety seems to be due to looser interactions in the adenine pocket, as typified by weaker hydrogen bonds to the hinge (including one CH-O bond) and less BSA. GRK2 is able to alter its configuration in order to conform to each particular analog, yielding three distinct crystal forms when in complex with benzodioxole warhead ligands (one paroxetine analog not reported in this paper was observed to crystallize in C222 1 , the same crystal form as the indazole-hybrids). Given their highly conserved active sites, the molecular basis for selectivity for GRK2 over other GRKs and AGC kinases is therefore most easily explained by the innate ability of GRK2 to accommodate these conformational changes.
This article has not been copyedited and formatted. The final version may differ from this version. Changing the identity of the hinge-binding moiety also affects how the D-ring packs, thereby influencing the conformation of residues in the aC helix and aB-aC loop that contacts the D ring, if present. Indeed, it was observed that there was a consistent shift of the aB-aC loop away from the active site in the indazole-hybrid complexes relative to those of the benzodioxole analogs. However, in the case of the CCG258748 complex this change in the aB-aC loop is subtler, which is most likely due to the interactions formed with the pyrazole D-ring of these compounds. In particular, the hydrogen bond formed between a pyrazole nitrogen and Glu239 in aC would restrict the movement of this loop. The outward movement of the aB-aC loop would create a slightly broader active site that could accommodate larger substituents, which could explain why bulky D-ring substituents like a 2,6-dimethoxybenzylamide showed very high potency in the GSK180736A series but not in the benzodioxole-paroxetine compounds (Waldschmidt et al., 2016 (Waldschmidt et al., , 2017 . Additionally, this shift of aB-aC loop may contribute to a kinase domain conformation that is more similar to that observed with other kinases such as GRK5 or PKA.
PCA revealed that the GRK2-Gbg complexes with indazole-paroxetine hybrid analogs adopt similar kinase domain conformations as complexes with GSK180736A analogs and the benzolactam-paroxetine analog (which all crystallized in the C222 1 crystal form). Interestingly, the kinase domain conformation in these complexes is also closely related to that of GRK5 bound to sangivamycin (PDB entry 4TNB) (Komolov et al., 2015) . This result could help explain why indazole-paroxetine hybrids are able to inhibit GRK5 more potently than the corresponding benzodioxole analogs, as they are able to trap the kinase domains of GRK2 and GRK5 in a similar conformational state. It should however be noted that the structure of GRK5
in complex with another indazole-based GSK180736A analog, CCG215022 (PDB entry 4WNK),
This article has not been copyedited and formatted. The final version may differ from this version. which is a pan-GRK inhibitor, adopted a distinct kinase conformation ( Figure 5) . Thus, the structure of a complex between GRK5 and an indazole-paroxetine hybrid would help to further elaborate on how GRK5 potency is gained. On the other hand, the benzodioxole analogs allow more conformational flexibility in the GRK2 kinase domain, as evidenced by the wider spread in PC space of 3V5W, 5UKK, 5UKM, and 5UKL, especially along the PC1 axis. This indicates once again that with respect to benzodioxole moieties, selectivity is likely driven by the apparently unique ability of GRK2 to mold itself to these ligands. Notably, another highly selective GRK2 inhibitor, CMPD101 (115h), also forms relatively weak interactions with the hinge via a pyridine moiety, and crystallized in complex with GRK2 in one of the C2 crystal forms (Thal et al., 2011; Okawa et al., 2017) . Given that the unique conformational space sampled by the kinase domains of GRK2 and GRK5 seems to be a major determinant of selectivity, it will be important to take their differing landscapes into account as one looks towards the rational design of GRK5-selective inhibitors.
This article has not been copyedited and formatted. The final version may differ from this version. shown in blue and GRK2-Gbg·CCG211998 (PDB ID: 5UKK) in magenta. C) GRK2-Gbg·CCG258748 is shown in green and GRK2-Gbg·CCG258208 (PDB ID: 5UKM) in orange. Values represent the mean contraction amplitude (as a percentage of cell length) ± standard error of the mean for 6-8 cardiomyocytes. Statistical significance (*p < 0.05) was determined in comparison to the DMSO control by a oneway ANOVA followed by Dunnet's test.
This article has not been copyedited and formatted. The final version may differ from this version. Plasma concentrations are the mean from three mice for each time point, error is expressed as the standard deviation.
This article has not been copyedited and formatted. The final version may differ from this version. 
